Dr. Craig H. Moskowitz, MD

Expert Publications

• High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
• Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
• Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
• Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
• Mantle cell lymphomas.
• Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
• Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
• Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
• CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen.
• Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
• High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
• Controversies in the treatment of lymphoma with autologous transplantation.

Media Releases

Get to know Hematologist-Oncologist Dr. Craig H. Moskowitz, who serves patients in Miami, Florida.

Dr. Moskowitz is an internationally recognized leader in lymphoma clinical research and treatment, specializing in the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.

As the Physician-in-Chief of the Oncology Service Line at the University of Miami Sylvester Comprehensive Cancer Center, he is responsible for the development, implementation, and administration of high quality, value-based oncology care at the main campus and satellites. He works across departments to improve the multidisciplinary care of cancer patients. 

As the leader of the Site Disease Groups, Dr. Moskowitz collaborates with group directors to enhance the patient navigation system and fosters multidisciplinary participation in the development and piloting of clinical trials.

Teaching students, he serves as a Professor within the Department of Medicine, Division of Medicine at the University of Miami Leonard M. Miller School of Medicine.

In regards to his educational background, Dr. Moskowitz graduated with his Bachelor of Science degree from Brooklyn College in 1980. He then went on to earn his medical degree from the Wayne State University School of Medicine in 1988.

Furthering his training, he performed his residency in internal medicine at Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses) in 1992, and his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in 1995.

Licensed to practice medicine in Florida and New York, the doctor is board-certified in medical oncology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Practice-changing, Dr. Moskowitz’s research focuses on improving the outcomes of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma. It has led to changes in the international standard of care for lymphoma patients. 

One area of accomplishment has been to optimize high-dose therapy and autologous stem cell transplantation, as well as new agents, to improve “salvage” therapy for patients with disease that has returned or is not responding to standard therapy. His second area of accomplishment has been to develop strategies that optimize the treatment of newly diagnosed DLBCL patients, according to the likelihood of their disease recurring. These include designing risk-adapted therapies, based on risk factors present before treatment and also the results of imaging studies. 

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Having been recognized for his research on a national level through multiple awards, Dr. Moskowitz has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is a member of the research council at MSKCC, and on the steering committees for the bi-annual international lymphoma conference in Lugano and the international Hodgkin lymphoma conference in Cologne.

Recommended Articles

• Wigs During Cancer Treatment: To Wear or Not To Wear?

  Many cancer patients have to go through round after round of chemotherapy treatment during their recovery program. One of the most common side effects of the radiation is loss of hair, especially on the head. This can potentially lead to a lot of issues for cancer patients in terms of their...

• How Julia Louis-Dreyfus Battles Breast Cancer Diagnosis

  Most people never actually get the chance to meet the celebrities they watch on TV or in the movies. An occasional sighting on the street or maybe a chance encounter often makes for great stories that get told at dinner parties for years to come.Even though many don’t usually have the chance to...

• Designer Bargains Raise $3 Million for Ovarian Cancer Research

  Photo credit: Hamptons MonthlyResearchers worldwide have been diligently conducting as many studies as possible trying to find treatments and ultimately a cure for ovarian cancer. However, there is a major problem with conducting cancer research: It’s expensive. In order to conduct these studies...

• What Specialist Conducts Chemotherapy?

  Chemotherapy is a very delicate and complicated procedure. This is because it also has the ability to cause further complications in a person’s health while it is being used to treat another medical condition. Chemotherapy usually has side effects that can be very severe.Therefore it requires well...

• What is Testicular Cancer: Get the Facts

  Testicular cancer is a malignancy that affects the testes, which are the sex glands in men that are responsible for secreting the male sex hormone testosterone and for producing sperm cells that fertilize female eggs to kick start a pregnancy.Prevalence of testicular cancerIn the United States,...

• Why Clinical Trials Are Essential for Advancement in Ovarian Cancer Treatment

  Women who have ovarian cancer need to understand that the best hope for improved screening methods and more effective treatments lies within their participation in clinical trials. Research is the cornerstone of improved medical advances, but work needs to be done at every level and for every stage...